Immune Design Corp. has entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy with Sanofi Pasteur, the vaccines division of Sanofi.   Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine candidate to the collaboration, and Immune Design will contribute G103, its preclinical trivalent vaccine candidate. The collaboration will explore the potential of various combinations of agents, including leveraging Immune De...